Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study

• Helen Kovari ,

  * E-mail: helen.kovari@usz.ch

  Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland

  ⨯
• Stefan Russmann,

  Affiliation Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland

  ⨯
• Bruno Ledergerber,

  Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland

  ⨯
• Daniel Müller,

  Affiliation Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland

  ⨯
• Margalida Rotger,

  Affiliation Institute of Microbiology, University Hospital, Lausanne, Switzerland

  ⨯
• Pablo Velli,

  Affiliation Institute of Microbiology, University Hospital, Lausanne, Switzerland

  ⨯
• Matthias Cavassini,

  Affiliation Division of Infectious Diseases, University Hospital, Lausanne, Switzerland

  ⨯
• Juan Ambrosioni,

  Affiliation Division of Infectious Diseases, University Hospital, Geneva, Switzerland

  ⨯
• Andrea Bregenzer,

  Affiliation Division of Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland

  ⨯
• Marcel Stöckle,

  Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Basle, Switzerland

  ⨯
• Enos Bernasconi,

  Affiliation Ospedale Regionale, Lugano, Switzerland

  ⨯
• Andri Rauch,

  Affiliation University Clinic of Infectious Diseases, University Hospital Berne and University of Berne, Berne, Switzerland

  ⨯
• Roberto F. Speck,

  Affiliation Division of Infectious Diseases and Hospital Epidemiology, University Hospital, University of Zurich, Zurich, Switzerland

  ⨯
• the Swiss HIV Cohort Study

  ¶Membership of the Swiss HIV Cohort Study is provided in the Acknowledgments.

  ⨯